All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

*Mycobacterium tuberculosis* (*Mtb*) is a worldwide public health threat responsible for approximately 8.6 million incident cases of tuberculosis (TB) and an estimated 1.3 million deaths annually \[[@pone.0120470.ref001]\]. The emergence and increasing prevalence of *Mtb* strains resistant to first and second line antituberculous medications are exacerbating the global TB epidemic \[[@pone.0120470.ref002]\]. Multidrug resistant (MDR) strains are *Mtb* strains resistant to both rifampicin (RIF) and isoniazid (INH), the most effective first-line drugs. Extensively drug resistant (XDR) *Mtb* strains, are defined as strains with MDR plus resistance to any fluoroquinolone (FQ) and one of the second-line injectable drugs used commonly for treating TB \[[@pone.0120470.ref003]\]. As of 2012, the World Health Organization (WHO) estimated the global prevalence of MDR-TB to be 3.6% among new TB cases and 20% among recurrent TB cases \[[@pone.0120470.ref001]\].

As M/XDR-TB rates continue to increase, the development and implementation of rapid diagnostic systems for the detection of microbial resistance to prevent further transmission and promptly implement appropriate drug regimens are needed \[[@pone.0120470.ref004]\]. Automated liquid culture systems have significantly shortened turnaround times for drug susceptibility tests (DSTs) compared to solid media, but bacteriological assays are technically demanding and still require a sophisticated biosafety environment and approximately 7 to 10 days to complete \[[@pone.0120470.ref004]\]. Detection of genetic mutations that confer resistance to certain antimicrobial agents represents a more rapid alternative \[[@pone.0120470.ref004]\]. Currently, the only broadly available commercial assay for the rapid detection of second-line-drug resistance, including FQ resistance, the MTBDR*sl* assay (Hain Lifescience, Nehren, Germany), detects only the most common mutations found in the quinolone resistance determining region (QRDR) of *gyrA \[[@pone.0120470.ref005]\].*

The main cellular target of FQs in *Mtb* is the DNA gyrase, a type II topoisomerase, which consists of two A and two B subunits encoded by *gyrA* and *gyrB* genes, respectively \[[@pone.0120470.ref002]\]. The genetic mechanism of resistance to FQs is a result of changes in the DNA gyrase, particularly, mutations in the QRDR of *gyrA* (codons 74 to 113) \[[@pone.0120470.ref006]\] and *gyrB* (codons 500 to 538) \[[@pone.0120470.ref007]\]. It has been estimated that roughly 60 to 90% of *Mtb* clinical isolates with FQ resistance have mutations in the QRDR of *gyrA*, particularly in codons 88, 90, 91, and 94 \[[@pone.0120470.ref008]--[@pone.0120470.ref010]\]. Mutations in *gyrB* have also been associated with FQ resistance, but with lower sensitivity and specificity, and they often co-occur with canonical *gyrA* mutations \[[@pone.0120470.ref011]--[@pone.0120470.ref015]\] and most often occur in codons 500 and 538 \[[@pone.0120470.ref016]\]. While most *Mtb* strains with *gyrA* mutations in the QRDR are FQ resistant, nearly all isolates with a wild type QRDR are FQ susceptible. The exceptions are the polymorphisms of *gyrA* at codons 21, 95 and 668 \[[@pone.0120470.ref014], [@pone.0120470.ref017], [@pone.0120470.ref018]\], which do not appear to be related to resistance.

FQs have potent *in vitro* activities against *Mtb* \[[@pone.0120470.ref019]\]. However, FQs are widely used to treat bacterial infections of the respiratory, gastrointestinal, and urinary tract as well as sexually transmitted diseases, further contributing to the increasing levels of FQ resistance in *Mtb* \[[@pone.0120470.ref020], [@pone.0120470.ref021]\]. FQs have proven to be among the most effective second-line anti-mycobacterial drugs \[[@pone.0120470.ref014], [@pone.0120470.ref021]\] and are recommended for the treatment of drug-resistant TB and for persons intolerant of current first-line therapy \[[@pone.0120470.ref017], [@pone.0120470.ref022]\]. While resistance to some of the older generation of FQs has been shown to emerge during treatment of patients infected with FQ-susceptible strains \[[@pone.0120470.ref020]\], newer generation FQs have become vital in the successful treatment of drug resistant TB \[[@pone.0120470.ref002], [@pone.0120470.ref003], [@pone.0120470.ref023]\]. As a result of the promising clinical activity of these newer FQs, the WHO currently recommends levofloxacin or moxifloxacin for the treatment of XDR-TB when ofloxacin resistance is present \[[@pone.0120470.ref024], [@pone.0120470.ref025]\].

In order to characterize the *gyrA* and *gyrB* mutations associated with global phenotypic resistance to the most commonly used FQs in *Mtb* we conducted a systematic review of English language studies from May 1996 to April 2013. The overall goals of the study were to: 1) characterize the diversity and frequency of *gyrA* and *gyrB* mutations in FQ resistant *Mtb* and 2) to describe the global distribution of these mutations to help determine their potential utility and reliability as diagnostic markers for detecting phenotypic FQ resistance in *Mtb*.

Methods {#sec006}
=======

Literature Search {#sec007}
-----------------

A Medline search was conducted of all publications investigating *gyrA* and *gyrB* mutations associated with phenotypic FQ resistance in *Mtb*. The search was restricted to studies published from May 1996 through April 15, 2013, including those studies available online prior to publication. MEDLINE/PubMed key search terms used with the help of Boolean operators ('and', 'or') were: "tuberculosis," "fluoroquinolone," "resistance," "resistant" "*gyrA*," "*gyrB*," "mutation," "sequence."

Study Selection Criteria {#sec008}
------------------------

Study selection criteria were similar to those described in Georghiou et al. \[[@pone.0120470.ref026]\]. Studies were included if they met the following predetermined criteria: i) published in English ii) presented original data and iii) assessed drug resistance mutations in clinical *Mtb* strains resistant to FQs (*in vitro* studies were excluded as laboratory generated mutations have been observed to be different from those found in clinical isolates) \[[@pone.0120470.ref027]\]. Studies were also excluded if they did not mention the specific FQ tested, did not perform or describe details of phenotypic drug susceptibility testing, did not perform sequencing as a method for determining mutations associated with drug resistance. Additionally, studies were excluded if they did not mention the country the clinical isolates originated from or if they listed multiple countries and did not distinguish clinical isolates by country.

Data Extraction and Entry {#sec009}
-------------------------

The following background variables were collected from the selected publications: author(s), year of publication, geographic origin of clinical strains, the reference strain used, methods for testing phenotypic drug susceptibility and genotypic mutations, MIC levels for each drug, genes sequenced, and loci of genes sequenced. The following mutation information was also recorded: specific gene mutation(s) found, FQ drug utilized for selection, number of resistant and susceptible isolates tested, and number of resistant and susceptible isolates demonstrating a mutation. Data was recorded and compiled using Microsoft Excel (Microsoft, Redmond, WA).

Data Collation and Cumulative Mutation Frequency Calculations {#sec010}
-------------------------------------------------------------

Data concerning mutations associated with FQ resistance were grouped by gene and stratified by the drug resistance phenotype associated with the mutation. Studies that specifically reported multiple mutations within a gene were also analyzed separately in order to determine the frequency of multiple mutations in genes associated with FQ resistance. Each mutation reported in a resistant *Mtb* isolate was considered independent of all others within and between studies (except where otherwise noted for multiple mutations in the same gene) and recorded as one instance of the mutation in the numerator of the cumulative mutation frequency calculations. Cumulative mutation frequency in *resistant* isolates was calculated as the number of resistant isolates in which the mutation was found, divided by the total number of phenotypically resistant isolates tested across studies. Cumulative mutation frequency in *susceptible* isolates was calculated as the number of susceptible isolates in which the mutation was found, divided by the total number of susceptible isolates tested across studies. As not all studies examined all mutations or all genes associated with resistance, isolates from a study were only included in the denominator of a cumulative frequency mutation calculation for a particular mutation if that mutation could have been detected in that study (i.e. the study sequenced the appropriate section of the gene). In order to accurately assess which gene fragments had been sequenced for each isolate, the exact start and end points of the gene fragments sequenced had to be determined. These endpoints were identified by entering the published primer sequences into the NCBI BLAST (Basic Local Alignment Search Tool) with *Mtb* H37Rv complete genome selected as the reference genome, Accession number NC_000962.3 and mapping the coordinates on *Mtb* H37Rv. Sequence fragments were inferred for articles that did not include primer sequences by using the outermost identified mutations as sequence endpoints. If several primers were included and sequenced fragments overlapped, the final dataset included only the outermost/inclusive primers.

The cumulative mutation frequency tables presented in the main body of the review represent the mutations that reached a frequency threshold, described as the following: 1) Isolates were included if a mutation was observed in at least two studies and reported resistance to at least two FQs with a frequency of at least 1% for any one of the FQs tested; 2) Mutations were excluded from the main tables when the frequencies of the mutation were equal in resistant and susceptible strains. Due to the large number of mutations reported (146 total), this frequency threshold was used to report only the most frequently reported mutations in the main tables. All mutations not meeting the above mentioned criteria, are available in [S1 Table](#pone.0120470.s001){ref-type="supplementary-material"}.

Results {#sec011}
=======

Description of Included Studies {#sec012}
-------------------------------

[Fig. 1](#pone.0120470.g001){ref-type="fig"} illustrates the study selection and exclusion process utilized for this review. Initial search parameters identified 193 studies published from May, 1996 through April 15, 2013. Forty-six publications met all eligibility criteria and were included in the review \[[@pone.0120470.ref003], [@pone.0120470.ref004], [@pone.0120470.ref008]--[@pone.0120470.ref010], [@pone.0120470.ref012], [@pone.0120470.ref015], [@pone.0120470.ref018], [@pone.0120470.ref020], [@pone.0120470.ref022], [@pone.0120470.ref027]--[@pone.0120470.ref062]\]. (PRISMA checklist included in [S2 Table](#pone.0120470.s002){ref-type="supplementary-material"}).

![Study Selection Process and Reason for Exclusion of Studies.](pone.0120470.g001){#pone.0120470.g001}

Of the 46 studies included, the earliest was published in 1996, with 23 (50%) published in the last three years ([Table 1](#pone.0120470.t001){ref-type="table"}). Altogether, mutation data was provided for 3,846 unique clinical *Mtb* isolates with various phenotypic resistance profiles to FQs. The reported geographic origins of these strains were diverse, covering four continents and 18 countries.

10.1371/journal.pone.0120470.t001

###### Details of Studies Included in Review and Source of *Mycobacterium tuberculosis* Isolates.

![](pone.0120470.t001){#pone.0120470.t001g}

  PubMed ID   Author (Year)              \# of FLQ Isolates Examined [⁺](#t001fn001){ref-type="table-fn"}   Origin of Isolates   Molecular Technique                             Clinical Institution(s) Providing Isolates                                 Year of Collection
  ----------- -------------------------- ------------------------------------------------------------------ -------------------- ----------------------------------------------- -------------------------------------------------------------------------- --------------------
  23491718    Chernyaeva et al. (2013)   50                                                                 Russia               Sequencing                                      TB Dispensary                                                              2011
  23561273    Jnawali et al. (2013)      123                                                                South Korea          PCR & Sequencing                                Korea Mycobacterium Resource Center                                        2009--2010
  23019190    Nosova et al. (2013)       68                                                                 Russia               Sequencing & TB-BIOCHIP-2                       Not Stated                                                                 Not Stated
  23146281    Poudel et al. (2013)       13                                                                 Nepal                PCR & Sequencing                                German Nepal Tuberculosis Project                                          2007--2010
  22552454    Chen et al. (2012)         93                                                                 China                PCR & Sequencing                                Not Stated                                                                 2009--2010
  22526012    Long et al. (2012)         177                                                                China                PCR & Sequencing                                National Tuberculosis Reference Laboratory                                 Not Stated
  22357804    Sirgel et al. (2012)       177                                                                South Africa         Sequencing                                      Not Stated                                                                 2007--2009
  22330913    Streicher et al. (2012)    181                                                                South Africa         Sequencing                                      National Health Laboratory Service                                         2006--2008
  22421328    Suzuki et al. (2012)       59                                                                 Japan                PCR & Sequencing                                11 Hospitals in Japan                                                      Not Stated
  23205246    Tahmasebi et al. (2012)    97                                                                 Iran                 PCR-SSCP & Sequencing                           Mycobacteriology Research Center, Masih Daneshvari Hospital                Not Stated
  22553245    Yuan et al. (2012)         58                                                                 China                PCR & Sequencing                                Jiangxi Chest Hospital                                                     2010--2011
  22560167    Zhu et al. (2012)          227                                                                China                PCR & Sequencing                                Not Stated                                                                 2007--2010
  21911575    Ali et al. (2011)          39[†](#t001fn002){ref-type="table-fn"}                             Pakistan             PCR & Sequencing                                Aga Khan University Clinical Microbiology Laboratory                       2004--2009
  22152119    Anand et al. (2011)        39                                                                 India                Sequencing                                      Not Stated                                                                 Not Stated
  21051549    Ando et al. (2011)         33                                                                 Japan                PCR, Sequencing & LiPA                          Nine Hospitals in Japan                                                    2002
  17                                     National Center for Global Health and Medicine                     2003--2008                                                                                                                                      
  21443804    Cui et al. (2011)          192                                                                China                PCR & Sequencing                                Not Stated                                                                 2009
  21653760    El Sahly et al. (2011)     36                                                                 United States        Sequencing                                      Mycobacteriology Laboratory at Texas Department of State Health Services   2007--2008
  21562102    Huang et al. (2011)        74[‡](#t001fn003){ref-type="table-fn"}                             Taiwan               GenoType MTBDRsl & PCR                          Various Hospitals                                                          2008--2009
  21450523    Hu et al. (2011)           31                                                                 China                Sequencing                                      Local TB Dispensaries                                                      2004--2005
  21632897    Kontsevaya et al. (2011)   51                                                                 Russia               Sequencing, Pyrosequencing & GenoType MTBDRsl   Various TB Clinics in Samara Region, Russian Federation                    2008
  21555766    Sekiguchi et al. (2011)    11                                                                 Japan                PCR                                             Not Stated                                                                 Not Stated
  21623040    Singh et al. (2011)        8                                                                  India                PCR & Sequencing                                Mycobacterial Repository Centre of the Institute                           2004--2008
  22115861    Zhao et al. (2011)         125                                                                China                MAS-PCR, PCR-RFLP & Sequencing                  Not Stated                                                                 Not Stated
  20335420    Brossier et al. (2010)     52                                                                 France               Sequencing & GenoType MTBDRsl                   French Reference Center for Mycobacteria                                   2005--2009
  20573868    Kiet et al. (2010)         62                                                                 Vietnam              Sequencing & GenoType MTBDRsl                   Pham Ngoc Thach Hospital                                                   2005--2006
  20956608    Lau et al. (2010)          71                                                                 China                PCR & Sequencing                                Queen Mary Hospital and Grantham Hospital                                  2003--2007
  99          2008--2009                                                                                                                                                                                                                                    
  20452372    Yin et al. (2010)          62                                                                 China                PCR & Sequencing                                Guangdong Chest Hospital                                                   2008--2009
  19846642    Bravo et al. (2009)        102                                                                Philippines          PCR & Pyrosequencing                            University of the Philippines-Philippine General Hospital                  Not Stated
  19721073    Duong et al. (2009)        109                                                                Vietnam              Sequencing                                      Pham Ngoc Thach Hospital                                                   2005--2007
  19386845    Hillemann et al. (2009)    106                                                                Germany              Sequencing & GenoType MTBDRsl                   National Reference Laboratory                                              Not Stated
  20028780    Perdigao et al. (2009)     26                                                                 Portugal             PCR & Sequencing                                Hospitals and Laboratories in Lisbon\'s Health Region                      2005
  19024017    Antonova et al. (2008)     107                                                                Russia               PCR, Biochip & Sequencing                       Not Stated                                                                 Not Stated
  18559646    Mokrousov et al. (2008)    71                                                                 Russia               PCR & Sequencing                                St. Petersburg Research Institute of Phthisiopulmonology                   2006
  18164184    Sun et al. (2008)          110                                                                China                PCR, DHPLC & Sequencing                         Beijing Chest Hospital                                                     2002--2004
  18544197    van Doorn et al. (2008)    82                                                                 Vietnam              PCR, RT-PCR & Sequencing                        Pham Ngoc Thach Hospital                                                   2005--2006
  17360809    Chan et al. (2007)         250                                                                China                PCR-SSCP/ MPAC & Sequencing                     Grantham Hospital and Public Health Laboratory                             1994--2004
  17934259    Escribino et al. (2007)    18                                                                 Spain                PCR & Sequencing                                Not Stated                                                                 Not Stated
  17434825    Sulochana et al. (2007)    118                                                                India                PCR & Sequencing                                Not Stated                                                                 Not Stated
  17412727    Wang et al. (2007)         42                                                                 Taiwan               PCR & Sequencing                                Tertiary Care Referral Centre                                              2004--2005
  16584301    Kam at al. (2006)          143                                                                China                Sequencing                                      TB Reference Laboratory, Department of Health                              1999--2003
  16204341    Huang et al. (2005)        141                                                                Taiwan               PCR & Sequencing                                Kaohsiung Veterans General Hospital                                        1995--2003
  15195248    Post et al. (2004)         13                                                                 South Africa         Sequencing                                      Not Stated                                                                 Not Stated
  12044302    Lee et al. (2002)          100                                                                Singapore            PCR & Sequencing                                Central Tuberculosis Laboratory                                            Not Stated
  11796356    Siddiqi et al. (2002)      68                                                                 India                PCR & Sequencing                                Outpatient hospitals and National Mycobacterial Repository                 1995--1998
  8737156     Williams et al. (1996)     9                                                                  China                PCR & Sequencing                                Not Stated                                                                 Not Stated
  8896523     Xu et al. (1996)           19                                                                 United States        PCR & Sequencing                                Public Health Research Institute Tuberculosis Center                       Not Stated

⁺Does not include reference strain

†Included S95T; not reported here

‡Examined 234 isolates, reported 74

A total of 146 unique mutations were reported relative to the reference H37Rv genome: *gyrA* (76 unique mutations, 34 single mutations and 42 multiple mutations), *gyrB* (28 unique mutations, 25 single mutations and 3 multiple mutations) and *gyrA and gyrB* (42 multiple mutations). We evaluated the DST methods and critical drug concentrations used in each study to define whether a strain was phenotypically resistant or not. [Table 2](#pone.0120470.t002){ref-type="table"} shows the DST methods and critical concentrations used in each of the included studies and whether or not they conformed to published reference standards. The drug concentrations used in 35 of the 46 (76%) studies conformed to at least one national or international published standard, 4 (9%) studies were conducted in national reference laboratories. The remaining 7 (15%) studies did not document a specific reference laboratory standard.

10.1371/journal.pone.0120470.t002

###### Drug Susceptibility Testing (DST) Methods Employed in Publications.

![](pone.0120470.t002){#pone.0120470.t002g}

  Author                                           DST Method                                      Second Generation                                  Third Generation                                                                                                                                                                                                                                                                                                                                          Fourth Generation                                                                                                                                                                                                                                                                                                                                                                                                                    
  ------------------------------------------------ ----------------------------------------------- -------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------
  Tahmasebi \[[@pone.0120470.ref052]\] et al.      LJ                                              2.0[⁺](#t002fn003){ref-type="table-fn"}            ---                                                                                                                                                                                                                                                                                                                                                       ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Wang \[[@pone.0120470.ref020]\] et al.           LJ                                              2.0[⁺](#t002fn003){ref-type="table-fn"}            2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   1.0[^‡‡^](#t002fn008){ref-type="table-fn"}          ---                                                 ---                                                 0.5[^‡‡^](#t002fn008){ref-type="table-fn"}                                                                                                                                                                                                                               ---
  Hu \[[@pone.0120470.ref046]\] et al.             LJ                                              2.0[⁺](#t002fn003){ref-type="table-fn"}            2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   1.0[^‡‡^](#t002fn008){ref-type="table-fn"}          ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Chen \[[@pone.0120470.ref053]\] et al.           LJ                                              1.0--16.0[^††^](#t002fn007){ref-type="table-fn"}   2.0[⁺](#t002fn003){ref-type="table-fn"}--16.0[^†^](#t002fn004){ref-type="table-fn"}                                                                                                                                                                                                                                                                       ---                                                 [°](#t002fn009){ref-type="table-fn"}                0.125--8.0[^‡‡^](#t002fn008){ref-type="table-fn"}   0.125--16.0[^‡‡^](#t002fn008){ref-type="table-fn"}                                                                                                                                                                                                                       [°](#t002fn009){ref-type="table-fn"}
  Poudel \[[@pone.0120470.ref054]\] et al.         LJ                                              ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Yuan \[[@pone.0120470.ref055]\] et al.           LJ                                              ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 \-                                                                                                                                                                                                                                                                       ---
  Williams \[[@pone.0120470.ref031]\] et al.       LJ                                              ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Jnawali \[[@pone.0120470.ref056]\]et al.         LJ                                              ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Zhao \[[@pone.0120470.ref041]\] et al.           LJ                                              ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Brossier \[[@pone.0120470.ref047]\] et al.       LJ                                              ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Kiet \[[@pone.0120470.ref040]\] et al.           LJ                                              ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Duong \[[@pone.0120470.ref012]\] et al.          LJ                                              ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Mokrousov \[[@pone.0120470.ref008]\] et al.      LJ                                              ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  van Doorn \[[@pone.0120470.ref039]\]et al.       LJ                                              ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Hillemann \[[@pone.0120470.ref009]\] et al.      LJ/MGIT 960                                     ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Nosova \[[@pone.0120470.ref057]\] et al.         LJ                                              ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   2.0[⁺⁺](#t002fn006){ref-type="table-fn"}            ---                                                 0.5[⁺⁺](#t002fn006){ref-type="table-fn"}            0.5[⁺⁺](#t002fn006){ref-type="table-fn"}                                                                                                                                                                                                                                 ---
  Anand \[[@pone.0120470.ref022]\] et al.          LJ                                              ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}--4.0[^†^](#t002fn004){ref-type="table-fn"}                                                                                                                                                                                                                                                                        ---                                                 ---                                                 2.0--5.0[^‡‡^](#t002fn008){ref-type="table-fn"}     2.0--5.0[^‡‡^](#t002fn008){ref-type="table-fn"}                                                                                                                                                                                                                          ---
  Chernyaeva \[[@pone.0120470.ref051]\] et al.     LJ                                              ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}--10.0[⁺⁺](#t002fn006){ref-type="table-fn"}                                                                                                                                                                                                                                                                        ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Antonova \[[@pone.0120470.ref029]\] et al.       LJ                                              ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}, 10.0[^†^](#t002fn004){ref-type="table-fn"}                                                                                                                                                                                                                                                                       ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Long \[[@pone.0120470.ref062]\] et al.           LJ                                              ---                                                5.0--50.0[^†^](#t002fn004){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                           2.0--20.0[^‡‡^](#t002fn008){ref-type="table-fn"}    ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Kam \[[@pone.0120470.ref049]\] at al.            LJ/MGIT 960                                     ---                                                0.5[^‡^](#t002fn005){ref-type="table-fn"}, 1.0[^‡^](#t002fn005){ref-type="table-fn"}, 2.0[⁺](#t002fn003){ref-type="table-fn"}, 4.0[^†^](#t002fn004){ref-type="table-fn"}, 8.0[^†^](#t002fn004){ref-type="table-fn"}, 16.0[^†^](#t002fn004){ref-type="table-fn"}                                                                                           ---                                                 ---                                                 ---                                                 0.5[⁺](#t002fn003){ref-type="table-fn"}, 1.0[^‡‡^](#t002fn008){ref-type="table-fn"}, 2.0[^‡‡^](#t002fn008){ref-type="table-fn"}, 4.0[^‡‡^](#t002fn008){ref-type="table-fn"}, 8.00[^‡‡^](#t002fn008){ref-type="table-fn"}, 16.00[^‡‡^](#t002fn008){ref-type="table-fn"}   ---
  Sun \[[@pone.0120470.ref027]\] et al.            LJ                                              ---                                                0.5[^‡^](#t002fn005){ref-type="table-fn"}, 1.0[^‡^](#t002fn005){ref-type="table-fn"}, 2.0[⁺](#t002fn003){ref-type="table-fn"}, 4.0[^†^](#t002fn004){ref-type="table-fn"}, 8.0[^†^](#t002fn004){ref-type="table-fn"}, 10.0[^†^](#t002fn004){ref-type="table-fn"}, 16.0[^†^](#t002fn004){ref-type="table-fn"}, 20.0[^†^](#t002fn004){ref-type="table-fn"}   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Sulochana \[[@pone.0120470.ref038]\] et al.      LJ                                              ---                                                8.0[^†^](#t002fn004){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                 ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Chan \[[@pone.0120470.ref036]\] et al.           LJ                                              ---                                                ---                                                                                                                                                                                                                                                                                                                                                       ---                                                 ---                                                 ---                                                 4.8[⁺⁺](#t002fn006){ref-type="table-fn"}                                                                                                                                                                                                                                 ---
  Siddiqi \[[@pone.0120470.ref033]\] et al.        LJ                                              ---                                                ---                                                                                                                                                                                                                                                                                                                                                       ---                                                 ---                                                 ---                                                 2.0[^‡‡^](#t002fn008){ref-type="table-fn"}                                                                                                                                                                                                                               ---
  Perdigao \[[@pone.0120470.ref048]\]et al. 2007   BACTEC 460                                      ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Zhu \[[@pone.0120470.ref058]\] et al.            MGIT 960                                        ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Kontsevaya \[[@pone.0120470.ref004]\] et al.     MGIT 960                                        ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 2.0[^†^](#t002fn004){ref-type="table-fn"}                                                                                                                                                                                                                                ---
  Streicher \[[@pone.0120470.ref059]\] et al.      MGIT 960                                        ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Cui \[[@pone.0120470.ref015]\] et al.            MGIT 960                                        ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Sirgel \[[@pone.0120470.ref060]\] et al.         MGIT 960                                        ---                                                0.5--10.0[^††^](#t002fn007){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                          \-                                                  ---                                                 ---                                                 0.125--2.0[^††^](#t002fn007){ref-type="table-fn"}                                                                                                                                                                                                                        ---
  Singh \[[@pone.0120470.ref044]\] et al.          Middlebrook 7H9                                 ---                                                8.0[^†^](#t002fn004){ref-type="table-fn"}, 16.0[^†^](#t002fn004){ref-type="table-fn"}, 32.0[^†^](#t002fn004){ref-type="table-fn"}                                                                                                                                                                                                                         ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Sekiguchi \[[@pone.0120470.ref050]\] et al.      Middlebrook 7H10                                0.5[^‡^](#t002fn005){ref-type="table-fn"}          ---                                                                                                                                                                                                                                                                                                                                                       0.5[^‡^](#t002fn005){ref-type="table-fn"}           ---                                                 0.06[^‡^](#t002fn005){ref-type="table-fn"}          ---                                                                                                                                                                                                                                                                      ---
  Xu \[[@pone.0120470.ref032]\] et al.             Middlebrook 7H10                                2.0[⁺](#t002fn003){ref-type="table-fn"}            ---                                                                                                                                                                                                                                                                                                                                                       ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Ali \[[@pone.0120470.ref042]\] et al.            Middlebrook 7H11                                2.0[⁺](#t002fn003){ref-type="table-fn"}            ---                                                                                                                                                                                                                                                                                                                                                       ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Huang \[[@pone.0120470.ref045]\] et al.          Middlebrook 7H11                                2.0[⁺](#t002fn003){ref-type="table-fn"}            2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   1.0[^‡‡^](#t002fn008){ref-type="table-fn"}          ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Suzuki \[[@pone.0120470.ref061]\] et al.         Middlebrook 7H11                                6.25--50.0[^†^](#t002fn004){ref-type="table-fn"}   ---                                                                                                                                                                                                                                                                                                                                                       3.13--25.0[^‡‡^](#t002fn008){ref-type="table-fn"}   1.56--12.5[^‡‡^](#t002fn008){ref-type="table-fn"}   0.78--6.25[^‡‡^](#t002fn008){ref-type="table-fn"}   0.78--12.5[^‡‡^](#t002fn008){ref-type="table-fn"}                                                                                                                                                                                                                        0.39--12.5[^‡‡^](#t002fn008){ref-type="table-fn"}
  Escribano \[[@pone.0120470.ref037]\] et al.      Middlebrook 7H11                                16.0[^†^](#t002fn004){ref-type="table-fn"}         16.0[^†^](#t002fn004){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                8.0[^‡‡^](#t002fn008){ref-type="table-fn"}          ---                                                 2.0[^‡‡^](#t002fn008){ref-type="table-fn"}          4.0[^‡‡^](#t002fn008){ref-type="table-fn"}                                                                                                                                                                                                                               ---
  Bravo \[[@pone.0120470.ref010]\] et al.          Middlebrook 7H10                                ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Lau \[[@pone.0120470.ref018]\] et al.            Middlebrook 7H10                                ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 1.0[^‡‡^](#t002fn008){ref-type="table-fn"}                                                                                                                                                                                                                               ---
  Post \[[@pone.0120470.ref034]\] et al.           Middlebrook 7H10                                ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Huang \[[@pone.0120470.ref035]\] et al.          Middlebrook 7H11                                ---                                                2.0[⁺](#t002fn003){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                   ---                                                 ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Yin \[[@pone.0120470.ref028]\] et al.            Middlebrook 7H11                                ---                                                ---                                                                                                                                                                                                                                                                                                                                                       1.0, 10.0[^‡‡^](#t002fn008){ref-type="table-fn"}    ---                                                 ---                                                 ---                                                                                                                                                                                                                                                                      ---
  El Sahly \[[@pone.0120470.ref043]\] et al.       Agar proportion indirect susceptibility assay   ---                                                ---                                                                                                                                                                                                                                                                                                                                                       ---                                                 ---                                                 ---                                                 0.5[^‡‡^](#t002fn008){ref-type="table-fn"}                                                                                                                                                                                                                               ---
  Ando \[[@pone.0120470.ref003]\] et al.           Broth MIC; Egg based Ogawa medium               2.0--16.0[^‡‡^](#t002fn008){ref-type="table-fn"}   ---                                                                                                                                                                                                                                                                                                                                                       2.0--16.0[^‡‡^](#t002fn008){ref-type="table-fn"}    1.0--8.0[^‡‡^](#t002fn008){ref-type="table-fn"}     ---                                                 ---                                                                                                                                                                                                                                                                      ---
  Lee \[[@pone.0120470.ref030]\] et al.            E-test                                          ---                                                ---                                                                                                                                                                                                                                                                                                                                                       ---                                                 ---                                                 ---                                                 32.0[^‡‡^](#t002fn008){ref-type="table-fn"} [°](#t002fn009){ref-type="table-fn"}                                                                                                                                                                                         ---

CIPRO = Ciprofloxacin, GAT = Gatifloxacin, LEVO = Levofloxacin, MOX = Moxifloxacin, OFL = Ofloxacin, SITA = Sitafloxacin, SPX = Sparfloxacin, NM = MIC not mentioned, LJ = Lowenstein-Jensen

--- = Indicates fluoroquinolone not tested in this study

⁺DST conforms to published standard

†DST above published standard

‡DST below published standard

⁺⁺Absolute concentration, not yet validated

††DST range above and below published standard

‡‡No published standard

°In gyrB only

*gyrA* Mutations Associated with Fluoroquinolone Resistance {#sec013}
-----------------------------------------------------------

Of the 46 papers examined in this review, all 46 studied resistance-associated markers within *gyrA*. [Fig. 2](#pone.0120470.g002){ref-type="fig"} shows the *gyrA* studies as a heat map of the number of isolates evaluated in all 46 studies as well as the locations of the mutations found in *gyrA*. Thirty-four studies sequenced the QRDR of the *gyrA* gene,11 studies sequenced part of the QRDR of the *gyrA* gene; only one study sequenced the entire *gyrA* gene.

![Heat map of Reviewed Studies that Evaluated *gyrA* Gene Mutations in *Mtb*.\
Heat map of individual papers indicating the number of isolates and the region of the *gyrA* gene studied. The number of isolates testes ranges from 8 (light grey) to 227 (black). Red indicates that a mutation has been found.](pone.0120470.g002){#pone.0120470.g002}

[Table 3](#pone.0120470.t003){ref-type="table"} shows the cumulative frequencies of the most commonly reported mutations in the *gyrA* gene associated with resistance to the primary FQs across publications. Resistance to ofloxacin, levofloxacin and moxifloxacin was studied in the largest number of isolates, but it is important to note that the primary canonical mutations listed in [Table 3](#pone.0120470.t003){ref-type="table"} appeared to be associated with resistance to all of the clinically relevant FQs, suggesting some level of cross-resistance is likely. Additionally, a subset of studies specifically examined and found evidence of cross resistance associated with these mutations, for example, most moxifloxacin resistant isolates with the A90V mutation (18%) were also resistant to ofloxacin (17%).

10.1371/journal.pone.0120470.t003

###### Cumulative Frequencies of the Most Frequently Occurring Mutations within *gyrA* Gene among *Mycobacterium tuberculosis* Isolates Resistant to Fluoroquinolones.

Mutations are listed in order of descending frequency.

![](pone.0120470.t003){#pone.0120470.t003g}

  **Codon**   **Substitution**   **FLQ Tested**   **\# Resistant Isolates Examined**   **\# Susceptible Isolates Examined**   **\# Resistant Isolates with Mutation**   **\# Susceptible Isolates with Mutation**   **Frequency of Mutation among Resistant Isolates**   **Frequency of Mutation among Susceptible Isolates**
  ----------- ------------------ ---------------- ------------------------------------ -------------------------------------- ----------------------------------------- ------------------------------------------- ---------------------------------------------------- ------------------------------------------------------
  94          Asp→Gly            OFL              1995                                 1572                                   566                                       0                                           0.28                                                 0
  MOX         357                540              114                                  0                                      0.32                                      0                                                                                                
  LEVO        412                248              105                                  0                                      0.25                                      0                                                                                                
  CIPRO       334                287              81                                   0                                      0.24                                      0                                                                                                
  GAT         198                91               56                                   0                                      0.28                                      0                                                                                                
  SPX         109                0                23                                   0                                      0.21                                      NA                                                                                               
  SITA        59                 0                15                                   0                                      0.25                                      NA                                                                                               
  Asp→Ala     OFL                1995             1572                                 177                                    1                                         0.09                                        0                                                    
  MOX         357                540              43                                   0                                      0.12                                      0                                                                                                
  LEVO        412                248              46                                   0                                      0.11                                      0                                                                                                
  CIPRO       334                287              36                                   0                                      0.11                                      0                                                                                                
  GAT         198                91               26                                   0                                      0.13                                      0                                                                                                
  SPX         109                0                19                                   0                                      0.17                                      NA                                                                                               
  SITA        59                 0                10                                   0                                      0.17                                      NA                                                                                               
  Asp→Asn     OFL                1995             1572                                 122                                    1                                         0.06                                        0                                                    
  MOX         357                540              22                                   1                                      0.06                                      0                                                                                                
  LEVO        412                248              22                                   0                                      0.05                                      0                                                                                                
  CIPRO       334                287              28                                   1                                      0.08                                      0                                                                                                
  GAT         198                91               13                                   1                                      0.07                                      0.01                                                                                             
  SPX         109                0                5                                    0                                      0.05                                      NA                                                                                               
  SITA        59                 0                5                                    0                                      0.08                                      NA                                                                                               
  Asp→Tyr     OFL                1995             1572                                 79                                     0                                         0.04                                        0                                                    
  MOX         357                540              14                                   0                                      0.04                                      0                                                                                                
  LEVO        412                248              11                                   0                                      0.03                                      0                                                                                                
  CIPRO       334                287              19                                   0                                      0.06                                      0                                                                                                
  GAT         198                91               11                                   0                                      0.06                                      0                                                                                                
  SPX         109                0                6                                    0                                      0.06                                      NA                                                                                               
  SITA        59                 0                5                                    0                                      0.08                                      NA                                                                                               
  Asp→His     OFL                1995             1572                                 21                                     0                                         0.01                                        0                                                    
  MOX         357                540              4                                    0                                      0.01                                      0                                                                                                
  LEVO        412                248              3                                    0                                      0.01                                      0                                                                                                
  CIPRO       334                287              1                                    0                                      0                                         0                                                                                                
  GAT         198                91               1                                    0                                      0.01                                      0                                                                                                
  Asp→Val     OFL                1995             1572                                 4                                      0                                         0                                           0                                                    
  MOX         357                540              1                                    0                                      0                                         0                                                                                                
  LEVO        412                248              2                                    0                                      0                                         0                                                                                                
  CIPRO       334                287              2                                    0                                      0.01                                      0                                                                                                
  GAT         198                91               2                                    0                                      0.01                                      0                                                                                                
  SPX         109                0                1                                    0                                      0.01                                      NA                                                                                               
  SITA        59                 0                1                                    0                                      0.02                                      NA                                                                                               
  90          Ala→Val            OFL              1995                                 1572                                   330                                       4                                           0.17                                                 0
  MOX         357                540              65                                   0                                      0.18                                      0                                                                                                
  LEVO        412                248              82                                   0                                      0.2                                       0                                                                                                
  CIPRO       334                287              45                                   0                                      0.13                                      0                                                                                                
  GAT         198                91               36                                   0                                      0.18                                      0                                                                                                
  SPX         109                0                16                                   0                                      0.15                                      NA                                                                                               
  SITA        59                 0                12                                   0                                      0.2                                       NA                                                                                               
  91          Ser→Pro            OFL              1995                                 1572                                   84                                        0                                           0.04                                                 0
  MOX         357                540              14                                   0                                      0.04                                      0                                                                                                
  LEVO        412                248              9                                    0                                      0.02                                      0                                                                                                
  CIPRO       334                287              18                                   0                                      0.05                                      0                                                                                                
  GAT         198                91               7                                    0                                      0.04                                      0                                                                                                
  SPX         109                0                4                                    0                                      0.04                                      NA                                                                                               
  SITA        59                 0                4                                    0                                      0.07                                      NA                                                                                               
  88          Gly→Cys            OFL              1982                                 1504                                   17                                        0                                           0.01                                                 0
  MOX         357                540              5                                    0                                      0.01                                      0                                                                                                
  LEVO        412                248              2                                    0                                      0                                         0                                                                                                
  CIPRO       295                287              1                                    0                                      0                                         0                                                                                                
  GAT         198                91               2                                    0                                      0.01                                      0                                                                                                
  SPX         109                0                1                                    0                                      0.01                                      NA                                                                                               
  SITA        59                 0                1                                    0                                      0.02                                      NA                                                                                               
  126         Ala→Arg            OFL              1676                                 1283                                   4                                         0                                           0                                                    0
  MOX         335                523              2                                    0                                      0.01                                      0                                                                                                

CIPRO = Ciprofloxacin, GAT = Gatifloxacin, LEVO = Levofloxacin, MOX = Moxifloxacin, OFL = Ofloxacin, SITA = Sitafloxacin, SPX = Sparfloxacin, NA = Not Applicable

Eighty seven percent of the moxifloxacin resistant isolates and 83% of the ofloxacin resistant isolates had mutations in their *gyrA* genes, with most mutations occurring in codons 88--94 ([Table 3](#pone.0120470.t003){ref-type="table"}, [S1 Table](#pone.0120470.s001){ref-type="supplementary-material"} and [S3 Table](#pone.0120470.s003){ref-type="supplementary-material"}). The cumulative frequency of individual mutations associated with FQ resistance was highest for the *gyrA* mutation D94G, ranging from 21--32% in FQ-resistant isolates depending on the specific FQ tested. The *gyrA* A90V mutation was the second most frequent mutation observed in FQ resistant isolates, and was found in 13--20% of FQ-resistant isolates depending on the FQ tested. Across all drugs tested, the *gyrA* mutations G88C and D94V were least frequent (1--2%).

Most importantly, none of the mutations listed in [Table 3](#pone.0120470.t003){ref-type="table"} occurred in more than a few of the many thousands of FQ susceptible isolates evaluated. Of the 41 studies reporting single A90V mutations, only two studies (n = 4) reported the A90V mutation in FQ susceptible isolates. Two other mutations were reported in susceptible isolates: D94A and D94N, but less than 1% of susceptible isolates contained these mutations, leaving open the possibility these were likely phenotypic DST errors.

*gyrB* Mutations Associated with Fluoroquinolone Resistance {#sec014}
-----------------------------------------------------------

Eighteen of the 46 (39%) publications included sequence data for *gyrB*. However, overall the *gyrB* mutations have only been evaluated in a few hundred FQ-resistant strains. Mutations of the *gyrB* gene occurred most frequently within ofloxacin resistant isolates ([Table 4](#pone.0120470.t004){ref-type="table"}). The *gyrB* N538D mutation (also reported as N510D in some publications depending on the numbering system used), as well as D500H, T539N and A543V were reported to be rare among ofloxacin-resistant isolates, at frequencies of less than 1%. While the number of susceptible isolates examined for *gyrB* mutations was low, it is important to note than none of them contained mutations listed in [Table 4](#pone.0120470.t004){ref-type="table"}.

10.1371/journal.pone.0120470.t004

###### Cumulative Frequencies of the Most Frequently Occurring Mutations within gyrB Gene among *Mycobacterium tuberculosis* Isolates Resistant to Fluoroquinolones.

Mutations are listed in order of descending frequency.

![](pone.0120470.t004){#pone.0120470.t004g}

  Codon   Substitution   FLQ Tested   \# Resistant Isolates Examined   \# Susceptible Isolates Examined   \# Resistant Isolates with Mutation   \# Susceptible Isolates with Mutation   Frequency of Mutation among Resistant Isolates   Frequency of Mutation among Susceptible Isolates
  ------- -------------- ------------ -------------------------------- ---------------------------------- ------------------------------------- --------------------------------------- ------------------------------------------------ --------------------------------------------------
  538     Asn→Asp        OFL          838                              393                                3                                     0                                       0.00                                             0.00
  MOX     118            70           2                                0                                  0.02                                  0.00                                                                                     
  LEVO    315            112          2                                0                                  0.01                                  0.00                                                                                     
  CIPRO   119            40           1                                0                                  0.01                                  0.00                                                                                     
  GAT     104            42           1                                0                                  0.01                                  0.00                                                                                     
  500     Asp→His        OFL          838                              393                                3                                     0                                       0.00                                             0.00
  MOX     118            70           1                                0                                  0.01                                  0.00                                                                                     
  LEVO    315            112          2                                0                                  0.01                                  0.00                                                                                     
  GAT     104            42           1                                0                                  0.01                                  0.00                                                                                     
  543     Ala→Val        OFL          536                              191                                4                                     0                                       0.01                                             0.00
  LEVO    137            40           2                                0                                  0.01                                  0.00                                                                                     
  539     Thr→Asn        OFL          708                              239                                2                                     0                                       0.00                                             0.00
  LEVO    256            42           2                                0                                  0.01                                  0.00                                                                                     

CIPRO = Ciprofloxacin, GAT = Gatifloxacin, LEVO = Levofloxacin, MOX = Moxifloxacin, OFL = Ofloxacin, NA = Not Applicable

Double Mutations in *gyrA* Associated with Fluoroquinolone Resistance {#sec015}
---------------------------------------------------------------------

Several studies reported double mutations in *gyrA*, *gyrB* or both *gyrA* and *gyrB*; [S3 Table](#pone.0120470.s003){ref-type="supplementary-material"} includes double mutations reported within the *gyrA* gene. The most commonly reported double mutations largely included the previously examined A90V mutation. While the cumulative frequencies of *gyrA* double mutations ranged from 1--3% among resistant isolates, no susceptible isolates were reported to contain any of the double mutations, suggesting that although rare, double *gyrA* mutations are highly specific predictors of FQ-resistance.

Mutations in *gyrA* Associated with Fluoroquinolone Resistance by Country {#sec016}
-------------------------------------------------------------------------

[Table 5](#pone.0120470.t005){ref-type="table"} shows the cumulative frequencies of *gyrA* point mutations in FQ resistant isolates by country. The greatest number of studies came from China (n = 13), followed by Russia (n = 5), with all other countries contributing less than four studies each. Both China and Russia reported the *gyrB* mutation D500H in FQ resistant isolates. In China, 85% of mutations reported were found in codons 88--94, whereas 89% of mutations in Russia were in these codons (the remainder of the mutations occurred outside of these codons and in *gyrB*). Of the 18 country-specific studies included in our review, 14 reported mutations in codon 90 (all in A90V) with frequencies ranging from 6% of FQ resistant strains in Iran to 30% of FQ resistant strains in the Philippines. Sixteen countries reported mutations in codon 94. For *gyrA* D94G, the cumulative frequency of the mutation in all FQ resistant strains ranged from 6% in Iran to 56% in South Korea. While A90V and D94G were the most frequently reported mutations overall, four countries reported mutations other than these mutations with higher frequency. In India, the most commonly reported mutation was D94A (20%); in Iran the most commonly reported mutation was D94N (11%); in Portugal the most commonly reported mutation was S91P (42%) and in Spain the most commonly reported mutation was D84G (17%).

10.1371/journal.pone.0120470.t005

###### Cumulative Frequencies of Selected Mutations within *gyrA* Gene among *Mycobacterium tuberculosis* Isolates by Country.

![](pone.0120470.t005){#pone.0120470.t005g}

  Country                 Mutation   \# Resistant Isolates Examined   \# Susceptible Isolates Examined   \# Resistant Isolates with Mutation   \# Susceptible Isolates with Mutation   Frequency of Mutation among Resistant Isolates   Frequency of Mutation among Susceptible Isolates
  ----------------------- ---------- -------------------------------- ---------------------------------- ------------------------------------- --------------------------------------- ------------------------------------------------ --------------------------------------------------
  China (n = 13)          A90V       1391                             1088                               253                                   0                                       0.18                                             0.00
  D94G                    1391       1088                             394                                0                                     0.28                                    0.00                                             
  D94A                    1391       1088                             111                                1                                     0.08                                    0.00                                             
  D94N                    1391       1088                             117                                4                                     0.08                                    0.00                                             
  S91P                    1391       1088                             51                                 0                                     0.04                                    0.00                                             
  D94Y                    1391       1088                             63                                 0                                     0.05                                    0.00                                             
  D94H                    1391       1088                             18                                 0                                     0.01                                    0.00                                             
  G88C                    1391       1088                             3                                  0                                     0.00                                    0.00                                             
  D500H                   674        220                              3                                  0                                     0.00                                    0.00                                             
  France (n = 1)          A90V       24                               28                                 4                                     0                                       0.17                                             0.00
  D94G                    24         28                               6                                  0                                     0.25                                    0.00                                             
  D94A                    24         28                               2                                  0                                     0.08                                    0.00                                             
  D94N                    24         28                               2                                  0                                     0.08                                    0.00                                             
  D94H                    24         28                               1                                  0                                     0.04                                    0.00                                             
  G88C                    24         28                               1                                  0                                     0.04                                    0.00                                             
  N538D                   24         28                               1                                  0                                     0.04                                    0.00                                             
  Germany (n = 1)         A90V       32                               74                                 4                                     0                                       0.13                                             0.00
  D94G                    32         74                               13                                 0                                     0.41                                    0.00                                             
  D94A                    32         74                               5                                  0                                     0.16                                    0.00                                             
  D94N                    32         74                               1                                  0                                     0.03                                    0.00                                             
  S91P                    32         74                               1                                  0                                     0.03                                    0.00                                             
  India (n = 4)           A90V       153                              158                                15                                    0                                       0.10                                             0.00
  D94G                    153        158                              14                                 0                                     0.09                                    0.00                                             
  D94A                    153        158                              31                                 0                                     0.20                                    0.00                                             
  D94N                    153        158                              4                                  0                                     0.03                                    0.00                                             
  S91P                    153        158                              2                                  0                                     0.01                                    0.00                                             
  D94Y                    153        158                              2                                  0                                     0.01                                    0.00                                             
  Iran (n = 1)            A90V       18                               79                                 1                                     0                                       0.06                                             0.00
  D94G                    18         79                               1                                  0                                     0.06                                    0.00                                             
  D94N                    18         79                               2                                  0                                     0.11                                    0.00                                             
  Japan (n = 3)           A90V       537                              0                                  93                                    0                                       0.17                                             NA
  D94G                    537        0                                120                                0                                     0.22                                    NA                                               
  D94A                    537        0                                90                                 0                                     0.17                                    NA                                               
  D94N                    537        0                                33                                 0                                     0.06                                    NA                                               
  S91P                    537        0                                24                                 0                                     0.04                                    NA                                               
  D94Y                    537        0                                36                                 0                                     0.07                                    NA                                               
  G88C                    537        0                                6                                  0                                     0.01                                    NA                                               
  Nepal (n = 1)           D94G       13                               0                                  7                                     0                                       0.54                                             NA
  D94A                    13         0                                2                                  0                                     0.15                                    NA                                               
  D94N                    13         0                                1                                  0                                     0.08                                    NA                                               
  S91P                    13         0                                1                                  0                                     0.08                                    NA                                               
  D94Y                    13         0                                1                                  0                                     0.08                                    NA                                               
  D94H                    13         0                                1                                  0                                     0.08                                    NA                                               
  Pakistan (n = 1)        A90V       39                               0                                  9                                     0                                       0.23                                             NA
  D94G                    39         0                                14                                 0                                     0.36                                    NA                                               
  D94A                    39         0                                2                                  0                                     0.05                                    NA                                               
  D94N                    39         0                                2                                  0                                     0.05                                    NA                                               
  S91P                    39         0                                1                                  0                                     0.03                                    NA                                               
  D94Y                    39         0                                5                                  0                                     0.13                                    NA                                               
  Philippines (n = 1)     A90V       10                               92                                 3                                     0                                       0.30                                             0.00
  D94G                    10         92                               3                                  0                                     0.30                                    0.00                                             
  Portugal (n = 1)        D94G       52                               0                                  12                                    0                                       0.23                                             NA
  D94A                    52         0                                16                                 0                                     0.31                                    NA                                               
  S91P                    52         0                                22                                 0                                     0.42                                    NA                                               
  Russia (n = 5)          A90V       364                              238                                67                                    3                                       0.18                                             0.01
  D94G                    364        238                              122                                0                                     0.34                                    0.00                                             
  D94A                    364        238                              42                                 0                                     0.12                                    0.00                                             
  D94N                    364        238                              14                                 0                                     0.04                                    0.00                                             
  S91P                    364        238                              10                                 0                                     0.03                                    0.00                                             
  D94Y                    364        238                              18                                 0                                     0.05                                    0.00                                             
  D94H                    364        238                              5                                  9                                     0.01                                    0.04                                             
  G88C                    364        238                              10                                 0                                     0.03                                    0.00                                             
  D500H                   250        143                              4                                  0                                     0.02                                    0.00                                             
  N538D                   250        143                              4                                  0                                     0.02                                    0.00                                             
  Singapore (n = 1)       D533A      48                               24                                 1                                     0                                       0.02                                             0.00
  South Africa (n = 3)    A90V       280                              258                                65                                    0                                       0.23                                             0.00
  D94G                    280        258                              92                                 0                                     0.33                                    0.00                                             
  D94A                    280        258                              30                                 0                                     0.11                                    0.00                                             
  D94N                    280        258                              27                                 0                                     0.10                                    0.00                                             
  S91P                    280        258                              15                                 0                                     0.05                                    0.00                                             
  D94Y                    280        258                              2                                  0                                     0.01                                    0.00                                             
  G88C                    275        250                              3                                  0                                     0.01                                    0.00                                             
  South Korea (n = 1)     A90V       108                              15                                 16                                    0                                       0.15                                             0.00
  D94G                    108        15                               60                                 0                                     0.56                                    0.00                                             
  D94A                    108        15                               2                                  0                                     0.02                                    0.00                                             
  D94N                    108        15                               3                                  0                                     0.03                                    0.00                                             
  S91P                    108        15                               9                                  0                                     0.08                                    0.00                                             
  D94Y                    108        15                               2                                  0                                     0.02                                    0.00                                             
  D94H                    108        15                               2                                  0                                     0.02                                    0.00                                             
  Spain (n = 1)           D84G       35                               60                                 5                                     0                                       0.14                                             0.00
  Taiwan (n = 3)          A90V       145                              520                                15                                    0                                       0.10                                             0.00
  D94G                    145        520                              51                                 0                                     0.35                                    0.00                                             
  D94A                    145        520                              3                                  0                                     0.02                                    0.00                                             
  D94N                    145        520                              5                                  0                                     0.03                                    0.00                                             
  S91P                    145        520                              2                                  0                                     0.01                                    0.00                                             
  D94Y                    145        520                              6                                  0                                     0.04                                    0.00                                             
  G88C                    145        520                              6                                  0                                     0.04                                    0.00                                             
  N538D                   56         112                              4                                  9                                     0.07                                    0.08                                             
  United States (n = 2)   A90V       23                               26                                 4                                     0                                       0.17                                             0.00
  D94G                    23         26                               3                                  0                                     0.13                                    0.00                                             
  D94A                    23         26                               1                                  0                                     0.04                                    0.00                                             
  D94N                    23         26                               3                                  0                                     0.13                                    0.00                                             
  D94Y                    23         26                               3                                  0                                     0.13                                    0.00                                             
  D94H                    23         26                               2                                  0                                     0.09                                    0.00                                             
  Vietnam (n = 3)         A90V       192                              40                                 37                                    0                                       0.19                                             0.00
  D94G                    192        40                               48                                 0                                     0.25                                    0.00                                             
  D94A                    192        40                               20                                 0                                     0.10                                    0.00                                             
  D94N                    192        40                               3                                  0                                     0.02                                    0.00                                             
  S91P                    192        40                               2                                  0                                     0.01                                    0.00                                             
  D94Y                    192        40                               7                                  0                                     0.04                                    0.00                                             
  D94H                    192        40                               1                                  0                                     0.01                                    0.00                                             

NA = Not applicable, division by zero

Discussion {#sec017}
==========

From the literature reviewed, it is evident that the QRDR of *gyrA* has been widely studied in FQ resistant *Mtb* isolates; while the remainder of the *gyrA* gene and the *gyrB* gene have been only rarely evaluated. In this review, we found that mutations occurring in the QRDR, specifically in codons 88--94, were found in 85% and 82% of phenotypic moxifloxacin and ofloxacin resistant strains, respectively. These results suggest that *gyrA* mutations in codons 88--94 are likely to be very sensitive markers of phenotypic resistance to FQ drugs in *Mtb* isolates, with high likelihood of cross-resistance to all the major FQs. Only one study included in the review sequenced the entire *gyrA* gene, explaining why very few mutations were reported outside of the QRDR region. The understudied *gyrA* regions may contain mutations that help explain the 15--18% of reported FQ resistant strains that did not appear to have mutations in codons 88--94 of the QRDR of *gyrA*. Additionally the 15--18% of FQ resistant *Mtb* strains with no identified mutation may possess an alternate mechanism of resistance \[[@pone.0120470.ref035], [@pone.0120470.ref063], [@pone.0120470.ref064]\]. Low cell wall permeability, efflux-related mechanisms, and drug sequestration or inactivation have been proposed to account for FQ resistance in these isolates \[[@pone.0120470.ref027], [@pone.0120470.ref064]\]. Equally important to the high frequency of the *gyrA* mutations in FQ resistant isolates, is the fact that these mutations occurred in only a few (\<1%) FQ susceptible isolates, suggesting that these mutations will have close to 100% specificity as markers of phenotypic FQ resistance. The very few susceptible isolates with QRDR mutations may also have been DST errors as most QRDR mutations (the canonical mutations) have been shown to confer resistance at WHO approved critical concentrations \[[@pone.0120470.ref021]\].

Mutations in the *Mtb gyrB* gene were also associated with FQ resistance but at a much lower frequency. In this study, these mutations were only evaluated in a few hundred FQ resistant strains and were rare (1--2% of FQ isolates observed). Mutations in *gyrB* typically occur in association with *gyrA* mutations \[[@pone.0120470.ref011]--[@pone.0120470.ref015]\] and most often occur in codons 500 and 538\[[@pone.0120470.ref016]\], making it difficult to assess their individual contributions to phenotypic resistance. In a recent study by Malik et al.\[[@pone.0120470.ref021]\] functional genetic analysis of *gyrB* indicated that certain mutations in *gyrB* confer FQ resistance, however the level and pattern of resistance varied among the different mutations. Nonetheless, the results from their study provide support for the inclusion of mutations in the QRDR of *gyrB* in next generation molecular assays used to detect FQ resistance in *Mtb*. In this review, some *gyrB* mutations did occur independently of *gyrA* mutations which could help explain the phenotypic resistance in isolates that don't have mutations in the QRDR region of *gyrA*. In our study, the most common *gyrB* mutations occurred in codons 500, 538, 539 and 543. No susceptible isolates were reported to contain *gyrB* mutations, suggesting these rare mutations are highly specific markers of FQ-resistance.

Although rare, *gyrA* double mutations were found to occur in codons 90 and 94. Double mutations suggest *Mtb* may be undergoing adaptive evolution to improve the fitness of the bacteria in response to global FQ treatment \[[@pone.0120470.ref065]\]. Although the data from this review were limited by the lack of geographical diversity of strains with double mutations, double *gyrA* mutations were never reported in FQ susceptible *Mtb* strains and are likely highly specific markers of FQ resistance in *Mtb*.

In this study, we noted that ofloxacin-resistant clinical isolates were consistently cross-resistant to the newer FQs (eg. moxifloxacin). While there is building evidence to suggest that certain *gyrA* mutations are associated with differential cross resistance to the different FQs, it would appear from our study that many of the canonical *gyrA* mutations should probably be considered broadly cross resistant while evidence of mutation-specific differential resistance is being verified.

The WHO has listed 27 "high burden" TB countries; data from seven of these countries (China, India, Pakistan, Philippines, Russia, South Africa and Vietnam) were included in this review. While several studies have commented on potential geographic differences \[[@pone.0120470.ref002], [@pone.0120470.ref015], [@pone.0120470.ref028], [@pone.0120470.ref040], [@pone.0120470.ref042], [@pone.0120470.ref045], [@pone.0120470.ref046], [@pone.0120470.ref051], [@pone.0120470.ref066]--[@pone.0120470.ref068]\] in frequencies of resistance conferring *gyrA* and *gyrB* mutations within and between countries, few attempts have been made to characterize these differences. In our study, we demonstrated that single *gyrA* mutations and resistance to FQs varies geographically. One possible reason for the diversity of mutations between countries may be attributed to different social and geographic transmission environments giving rise to different pressures of natural selection. A second possible reason for this diversity may be attributed to differences in treatment regimens containing FQs, which can result in geographically diverse drug-based selection pressures. Identifying geographical areas with high frequencies of unique mutations may help improve molecular surveillance methods and identify areas of concern for molecular diagnostic assay scale up. However, as long as next generation molecular diagnostics or whole gene/genome approaches are able to detect all of the canonical *gyrA* mutations known to confer resistance, and geographically diverse mutations show the same specificity, the observed spatial diversity of mutations will not decrease sensitivity or specificity of next generation assays.

The WHO Stop TB Program has emphasized the need to strengthen diagnostic testing and the need to develop rapid diagnostics \[[@pone.0120470.ref069]\]. The only commercial assay for rapid detection of FQ resistance in clinical samples currently is the MTBDR*sl* line probe assay (Hain Lifescience, Nehren, Germany). The MTBDR*sl* assay can detect *Mtb* mutations A90V, S91P, D94A, D94N/Y, D94G, and D94H, with a recently reported pooled sensitivity and specificity of 87% and 97% respectively on direct clinical samples \[[@pone.0120470.ref070]\]. While we did observe mutations in *gyrA* outside of the codons interrogated by the MTBDR*sl* assay, and in *gyrB* (1--2% of FQ-resistant strains showed single mutations in *gyrB*), our findings indicate that at least 85% and 82% of moxifloxacin and ofloxacin resistant strains, respectively, were observed to contain mutations in the codons interrogated by the MTBDR*sl* assay. This data is consistent with the pooled sensitivity of the MTBDR*sl* assay recently reported in a Cochrane review \[[@pone.0120470.ref071]\] and suggests that the MTBDR*sl* assay is likely to have good sensitivity for detection of moxifloxacin and ofloxacin resistance globally depending on its ability to detect these mutations in clinical samples. Based on the frequency of QRDR mutations observed in FQ resistant strains in China and Russia (83% and 84% respectively), the MTBDR*sl* assay may have a similar sensitivity in those countries. However, it is important to understand that biases in the collection of strains in the studies from those countries may have contributed to the frequencies observed. This emphasizes the need for representative national and global surveillance of resistance mutations to obtain more reliable estimates of global frequencies of these mutations in order to design next generation molecular diagnostics and optimize global performance.

Recently the WHO Expert Group concluded that based on available evidence, the GenoType MTBDR*sl* assay had a pooled sensitivity and specificity of 84% and 97% respectively. The expert panel determined that while the specificity was sufficient for a "rule-in" test of FQ resistance, it should not be used as a replacement test for conventional phenotypic testing yet \[[@pone.0120470.ref072]\] due to a high proportion of phenotypic FQ resistant isolates that it appears to be unable to detect. Our review of the global frequencies of *gyrA* mutations in FQ resistant isolates suggests that next generation assays able to detect all of the *gyrA* mutations presented in this review should have sensitivities of at least 87% and 83% for detection of moxifloxacin and ofloxacin resistance respectively, depending on their ability to detect these mutations in clinical samples. Based on our review and previously published work on *gyrA* frequencies by others \[[@pone.0120470.ref016], [@pone.0120470.ref073], [@pone.0120470.ref074]\], it seems unlikely that molecular diagnostics based on *gyrA* mutations alone will have global sensitivities exceeding 95%, and may suffer from geographic variability. But it is important to view this limitation in the context of the fact that less than 30--45% of MDR-TB, and likely less FQ resistant TB, is currently being detected by standard phenotypic methods \[[@pone.0120470.ref075]\]. Existing molecular diagnostics based on detection of QRDR mutations could significantly improve the number of FQ resistant TB cases being detected and treated appropriately.

Limitations {#sec018}
-----------

This study has several limitations. The cumulative frequencies calculated were based on two main assumptions. First, it was assumed that all the mutations reported were independent of each other. If some isolates were misclassified as independent when they were, in fact, not, this could have caused an overestimation in our cumulative frequencies of that specific mutation. Every effort was made to ensure that the isolates and the mutations presented in one study were not also reported in another study. Every manuscript was scrutinized for evidence of the same isolates being reported on and to the best of our knowledge all isolates reported were unique. A second potential source of misclassification error was in our use of the DST results as reported. For example, if an isolate was misclassified as resistant based on faulty DST data, when it was, in fact, susceptible, and it did not have the expected mutation then we would have underestimated the cumulative frequency of that mutation among resistant isolates. To minimize the chances of such misclassification, we excluded manuscripts with no explicit descriptions of their DST methods and clear definitions of what constituted a resistant or susceptible isolate using accepted DST drug concentrations and methodologies. For those studies that did not state which section of a gene was sequenced, this was assumed based on the mutations reported, possibly introducing misclassification bias. Identified "hot spots" were grouped by country (as not all studies reported the city the isolates were collected in) regardless of the year the isolates were collected. Additionally it was assumed that these mutations would remain in the same locations between the time the data were collected and the time of this publication. Moreover, studies reporting from only one country were generalized to the entire country, possibly introducing misclassification bias. Lastly, the exclusion of laboratory generated mutations may have led to the under-reporting of *gyrA* mutations. While laboratory generated mutations and clinical isolates have common features, they also have some key differences. Sun et al. \[[@pone.0120470.ref027]\]observed mutations occurring in clinical isolates most often did not occur in the laboratory generated mutations. Furthermore, clinical isolates and laboratory generated mutations differed in frequency for various mutation patterns. Thus, while laboratory generated mutations are critical to the understanding of the mechanism of mutations, these mutations do not always accurately reflect the mutations and frequencies of mutations observed in clinical isolates and were therefore excluded from this review of mutations for the purposes of understanding molecular diagnostics for clinical isolates.

Conclusion {#sec019}
==========

To maximize the sensitivity and specificity of molecular diagnostics based on detection of mutations conferring FQ resistance in *Mtb*, we need an understanding of the frequency and geographic distribution of these mutations. In this review, *gyrA* mutations reported in codons 88--94 appeared to account for at least 82% of phenotypic ofloxacin resistance and 85% of moxifloxacin resistance globally, while g*yrB* mutations and *gyrA* double mutations occurred only rarely. While we did observe geographic differences in the frequencies of specific *gyrA* mutations between countries, it is likely that next generation molecular assays that can detect all of the *gyrA* and *gyrB* mutations documented to confer resistance, will have good sensitivity and specificity globally. Using existing molecular diagnostics to rapidly detect FQ resistance in clinical *Mtb* strains could substantially enhance drug resistance control efforts, with the goal of interruption of disease transmission and ultimately incidence reduction, especially in countries with cross-resistance. While it appears the line probe assay, Genotype MTBDR*sl* should have good sensitivity and specificity for detecting phenotypic FQ resistance globally, future national and international surveillance studies focusing on prevalence of mutations across all of *gyrA* and *gyrB*, could improve design and optimization of next generation molecular diagnostics for detecting FQ resistance.
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